<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662502</url>
  </required_header>
  <id_info>
    <org_study_id>Floravie</org_study_id>
    <nct_id>NCT04662502</nct_id>
  </id_info>
  <brief_title>Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity</brief_title>
  <official_title>Observational, Prospective, Multicentric Study of the Effect of Bifidobacterium Longum 35624 on Quality of Life of Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocodex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocodex</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this observatory is to evaluate the effect of Bifidobacterium longum&#xD;
      35624 on the quality of life of IBS patients having different subtypes of transit pattern and&#xD;
      different level of symptom severity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observatory evaluate the effect of Bifidobacterium longum 35624 on the quality of life&#xD;
      of IBS patients having different subtypes of transit pattern and different level of symptom&#xD;
      severity, after a one-month treatment with Bibidobacterium longum 35624, 1x10^9 CFU/capsule,&#xD;
      1 capsule/day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2018</start_date>
  <completion_date type="Actual">June 26, 2020</completion_date>
  <primary_completion_date type="Actual">January 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL).</measure>
    <time_frame>Assessed at baseline and after 1 month of treatment</time_frame>
    <description>Change from baseline of quality of life as assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL, scoring from 0 to 100, with higher scores indicating better IBS specific quality of life) in IBS patients having different subtypes of transit pattern and different level of symptom severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life subscores assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL).</measure>
    <time_frame>Assessed at baseline and after 1 month of treatment</time_frame>
    <description>Change from baseline of quality of life subscores as assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL, scoring from 0 to 100, with higher scores indicating better IBS specific quality of life) in IBS patients having different subtypes of transit pattern and different level of symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS Symptom Severity</measure>
    <time_frame>Assessed at baseline and after 1 month of treatment</time_frame>
    <description>Change of IBS Symptom Severity assessed with the IBS Severity Scoring System (IBS-SSS, scoring from 0 to 500, with higher scores indicating worse severity of IBS symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Stool consistency</measure>
    <time_frame>Assessed at baseline, day10, day 20 and day 30</time_frame>
    <description>Change of stool consistency assessed with the Bristol stool scale. The Bristol Stool Chart classifies stool according to their shape and consistency and assigns a sample a number from 1-7 depending on its characteristics, corresponding to constipation normal or diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to the treatment</measure>
    <time_frame>Assessed after 1 month of treatment</time_frame>
    <description>Compliance assessed with patient self-report on a diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Assessed after 1 month of treatment</time_frame>
    <description>Patient satisfaction with treatment assessed on a 5-point Likert scale, with proposals ranked in ascending order of satisfaction as 1- Not at all satisfied; 2- Unsatisfied; 3- Somewhat satisfied; 4-Satisfied to 5-Very satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's overall impression after treatment</measure>
    <time_frame>Assessed after 1 month of treatment</time_frame>
    <description>The patient's overall impression of how the product has changed his or her daily activities, symptoms, and quality of life, assessed with the Patients' Global Impression of Change (PGIC) scale. PGIC is a 7-point scale describing patient's rating of overall improvement. Change is rated by patients as &quot;very much improved,&quot; &quot;much improved,&quot; &quot;minimally improved,&quot; &quot;no change,&quot; &quot;minimally worse,&quot; &quot;much worse,&quot; or &quot;very much worse.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's satisfaction</measure>
    <time_frame>Assessed after 1 month of treatment</time_frame>
    <description>Physician satisfaction with the treatment for his/her patient assessed on a 5-point Likert scale, with proposals ranked in ascending order of satisfaction as 1- Not at all satisfied; 2- Unsatisfied; 3- Somewhat satisfied; 4-Satisfied to 5-Very satisfied</description>
  </secondary_outcome>
  <enrollment type="Actual">220</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium longum 35624</intervention_name>
    <description>Bifidobacterium longum 35624, 1 x 10^9 CFU/capsule, 1 capsule/day over 1 month</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult outpatients with IBS consulting a gastroenterologist&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, at least 18 years of age&#xD;
&#xD;
          -  Gastroenterology consultation for an Irritable Bowel Syndrome according to Rome IV&#xD;
             criteria&#xD;
&#xD;
          -  Having received a first prescription of Bifidobacterium longum 35624 during the&#xD;
             consultation (independently of participation in the observatory)&#xD;
&#xD;
          -  Informed and having declared his/her non-opposition to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not having a good enough command of reading and comprehension of the French language&#xD;
             to correctly complete the questionnaires and the notebook&#xD;
&#xD;
          -  Having already taken Bifidobacterium longum 35624&#xD;
&#xD;
          -  Having received probiotics or antibiotics within 2 weeks previous&#xD;
&#xD;
          -  Having started within the last 7 days a treatment that can interfere with the&#xD;
             investigator's evaluation of the investigational product under investigation&#xD;
&#xD;
          -  Participant in another trial&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Being under guardianship or curator.&#xD;
&#xD;
          -  Not having a good enough command of reading and comprehension of the French language&#xD;
             to correctly complete the questionnaires and the notebook&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gyasi K Johnson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biocodex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

